Clinical trial NCT02061397: Safety of Simvastatin in LAM and TSC
Official title: The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Lymphangioleiomyomatosis
Tuberous Sclerosis Complex
Keywords: lymphangioleiomyomatosis (LAM)
tuberous sclerosis complex (TSC)
simvastatin
sirolimus
everolimus
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: The LAM Foundation
First posted: 2014-02-12
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to see if simvastatin can be taken safely in patients with either LAM or TSC, who are already being treated with everolimus or sirolimus. This is the first step in looking at simvastatin as a drug that may help patients, by impacting the growth and survival of cells that make up the lung lesions that cause problems in LAM and TSC patients. The study also seeks to learn more about how simvastatin works, when given to patients being treated with everolimus or sirolimus, and to evaluate the safety and any potential benefit to patients taking this 2-drug combination.

The primary objective of this study is to determine the safety of simvastatin in the treatment of LAM-S or LAM-TS in patients on a stable (for at least 3 months) dose of sirolimus or everolimus.

Secondary objectives include:

* To assess the effect of simvastatin on forced expiratory volume in 1 second (FEV1).
* To assess the effect of simvastatin on forced vital capacity (FVC).
* To assess the effect of simvastatin on diffusing lung capacity (DLCO).
* To assess the effect of simvastatin on vascular endothelial growth factor -D (VEGF-D) serum levels.
* To assess the effect of simvastatin with questionnaire- based assessments of dyspnea, fatigue, and quality of life (QOL).
* Assess signs of clinical benefit.

Detailed description: After providing written informed consent, study related tests/procedures will be done to ensure eligibility for the study. If found to be eligible, the participant will be given simvastatin at a starting dose of 20 mg, to be taken each evening by mouth. If after 2 months the simvastatin 20 mg dose is tolerated, the dose of simvastatin will be increased to 40 mg each evening by mouth. Doses may be adjusted as needed, should the participant experience side effects from simvastatin. The participant's dose of everolimus or sirolimus is not expected to change, as this is a dose that has been previously tolerated. If side effects occur as a result of the combination of drugs, the dosages may be adjusted by the study physician (investigator).

Eligibility criteria: Inclusion Criteria:

* Female, age 18 and older with clinically definitive diagnosis (biopsy proven or compatible chest CT/MRI scan) of sporadic LAM (LAM-S) or LAM associated with TS (LAM-TS).
* Treated with a stable (at least 3 months) dose of sirolimus or everolimus
* Negative pregnancy test (women of child bearing potential) at screening.
* Women of childbearing potential must be using barrier, medically acceptable contraceptive precautions.
* Signed and dated informed consent.

Exclusion Criteria:

* Age \< 18 years
* Known allergy to simvastatin or currently taking simvastatin, or therapy with a medication in the same class as simvastatin within the past 30 days.
* Allergy to sirolimus or everolimus.
* Current use of other than sirolimus or everolimus investigational drug for TSC or LAM within the past 30 days.
* Use of estrogen containing medications, including birth control pills, within the 30 days prior to enrollment.
* Treatment with drugs having known metabolic interactions with statin drugs (e.g. cytochrome P450 3A4 metabolism), including ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, azithromycin, niacin (nicotinic acid), digoxin, warfarin, sildenafil or use of strong CYP3A4 inhibitors including gemfibrozil, cyclosporine, danazol, verapamil, diltiazem, and dronedarone. amiodarone, amlodipine, and ranolazine.
* Participation in another clinical study(ies) of an investigational treatment or drug within 30 days prior to the screening visit.
* Amiodarone; within the past 30 days.
* Significant dysfunction of liver (ALT \> 2 times upper limit of normal-ULN), kidney (serum creatinine \> 1.5 times ULN), or blood (leucopenia (ANC\<2000), anemia, Hgb \< 11 gm/dl).
* History of inflammatory muscle disease or myopathy.
* Bleeding diathesis or anticoagulant therapy.
* Uncontrolled hyperlipidemia or diabetes.
* Pregnant, breast feeding, or plan to become pregnant within the next 6 months
* Inadequate contraception (must agree to barrier method)
* History of organ transplant.
* Active on transplant list.
* Severe or uncontrolled medical conditions which would cause an unacceptable safety risk or compromise compliance with the protocol.
* Unstable seizures (recent changes in pattern or anti-epileptics).
* Mental illness or cognitive deficit precluding informed consent..
* Inability to attend scheduled clinic visits or comply with study procedures.

Primary outcomes:
measure: Safety of Simvastatin in the Treatment of LAM-S and LAM-TS Patients
timeFrame: 5 months
Secondary outcomes:
measure: Percent Predicted FEV1
timeFrame: 5 months
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Vera P Krymskaya, PhD, MBA
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Pennsylvania
name: Maryl Kreider, MD, MSCE
role: STUDY_DIRECTOR
affiliation: University of Cincinnati
name: Frank McCormack, MD
role: STUDY_CHAIR
References:
citation: Krymskaya VP. Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges. Am J Respir Cell Mol Biol. 2012 May;46(5):563-5. doi: 10.1165/rcmb.2011-0381ED. No abstract available.
citation: Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, Krymskaya VP. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med. 2012 Oct 3;4(154):154ra134. doi: 10.1126/scitranslmed.3003840.
citation: Atochina-Vasserman EN, Goncharov DA, Volgina AV, Milavec M, James ML, Krymskaya VP. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling. Am J Respir Cell Mol Biol. 2013 Nov;49(5):704-9. doi: 10.1165/rcmb.2013-0203RC.
citation: Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, Krymskaya VP. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol. 2011 Jun;31(12):2484-98. doi: 10.1128/MCB.01061-10. Epub 2011 Apr 11.